<p>Agios 制药（AGIO）披露了一项新的风险，属于监管类别。</p>
<h3>情人节促销 - 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Agios 制药面临加剧的监管时机风险，因为资金削减、员工裁减以及 FDA 或外国机构的停摆可能会减缓或中断其产品候选的指导、审查和批准。这些延迟可能会实质性地妨碍其临床开发时间表，增加成本，并对其竞争地位和未来收入产生负面影响。</p>
<p>总体而言，华尔街对 AGIO 股票的共识评级为适度买入，基于 6 个买入和 3 个持有。</p>
<p>要了解更多关于 Agios 制药的风险因素，请点击这里。</p>

Agios制药

<p>Agios 制药（AGIO）面临监管延迟，这威胁到其药物研发管线和收入前景。FDA 的资金削减和人员减少可能会干扰其产品候选药物的审批过程，潜在地增加成本并影响竞争地位。尽管面临这些挑战，华尔街对 AGIO 股票仍维持适度买入的共识，评级为 6 个买入和 3 个持有</p>

<p>Agios Pharmaceuticals (AGIO) has disclosed a new risk, in the Regulation category.</p>
<div class="lb-trans"><p>Agios 制药（AGIO）披露了一项新的风险，属于监管类别。</p>
</div><h3>Valentine's Day Sale - 70% Off</h3>
<div class="lb-trans"><h3>情人节促销 - 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Agios Pharmaceuticals faces heightened regulatory timing risk as funding cuts, staff reductions and shutdowns at the FDA or foreign agencies could slow or disrupt guidance, review and approval of its product candidates. Such delays could materially hinder its clinical development timelines, increase costs and negatively affect its competitive position and future revenues.</p>
<div class="lb-trans"><p>Agios 制药面临加剧的监管时机风险，因为资金削减、员工裁减以及 FDA 或外国机构的停摆可能会减缓或中断其产品候选的指导、审查和批准。这些延迟可能会实质性地妨碍其临床开发时间表，增加成本，并对其竞争地位和未来收入产生负面影响。</p>
</div><p>Overall, Wall Street has a Moderate Buy consensus rating on AGIO stock based on 6 Buys and 3 Holds.</p>
<div class="lb-trans"><p>总体而言，华尔街对 AGIO 股票的共识评级为适度买入，基于 6 个买入和 3 个持有。</p>
</div><p>To learn more about Agios Pharmaceuticals’ risk factors, click here.</p>
<div class="lb-trans"><p>要了解更多关于 Agios 制药的风险因素，请点击这里。</p>
</div>

监管延迟可能威胁到 Agios 制药的药物研发管线、成本以及收入预期